| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/03/2023 | 24.56% | HC Wainwright & Co. | → $300 | Reiterates | Buy → Buy |
| 05/04/2023 | 6.29% | Ladenburg Thalmann | $285 → $256 | Maintains | Buy |
| 04/21/2023 | 16.25% | Argus Research | $300 → $280 | Maintains | Buy |
| 04/10/2023 | 28.71% | UBS | $330 → $310 | Maintains | Buy |
| 04/10/2023 | 31.2% | Morgan Stanley | $320 → $316 | Maintains | Overweight |
| 02/23/2023 | 16.25% | JP Morgan | $265 → $280 | Maintains | Overweight |
| 02/23/2023 | 32.86% | Morgan Stanley | $330 → $320 | Maintains | Overweight |
| 02/23/2023 | 24.56% | HC Wainwright & Co. | → $300 | Reiterates | → Buy |
| 01/11/2023 | 24.56% | Argus Research | $250 → $300 | Maintains | Buy |
| 12/06/2022 | 37.01% | Morgan Stanley | $322 → $330 | Maintains | Overweight |
| 12/06/2022 | 32.86% | UBS | → $320 | Initiates Coverage On | → Buy |
| 12/05/2022 | -4.5% | Goldman Sachs | → $230 | Initiates Coverage On | → Sell |
| 11/03/2022 | 10.03% | JP Morgan | $240 → $265 | Maintains | Overweight |
| 11/03/2022 | 33.69% | Morgan Stanley | $288 → $322 | Maintains | Overweight |
| 11/03/2022 | 55.7% | Oppenheimer | $325 → $375 | Maintains | Outperform |
| 11/03/2022 | 24.56% | HC Wainwright & Co. | $255 → $300 | Maintains | Buy |
| 10/11/2022 | 19.58% | Morgan Stanley | → $288 | Initiates Coverage On | → Overweight |
| 05/24/2022 | -1.18% | JP Morgan | $225 → $238 | Maintains | Overweight |
| 05/24/2022 | 1.72% | Jefferies | $223 → $245 | Maintains | Buy |
| 05/24/2022 | 9.2% | Wedbush | $236 → $263 | Maintains | Outperform |
| 05/24/2022 | 2.55% | Credit Suisse | $219 → $247 | Maintains | Outperform |
| 05/24/2022 | 5.88% | HC Wainwright & Co. | $248 → $255 | Maintains | Buy |
| 04/19/2022 | -7.41% | JP Morgan | $230 → $223 | Maintains | Overweight |
| 02/28/2022 | -2.01% | Wedbush | $276 → $236 | Maintains | Outperform |
| 02/25/2022 | -15.72% | Ladenburg Thalmann | $231 → $203 | Maintains | Buy |
| 02/11/2022 | — | BTIG | Initiates Coverage On | → Neutral | |
| 07/14/2021 | -14.88% | Argus Research | → $205 | Upgrades | Hold → Buy |
| 05/06/2021 | 2.97% | HC Wainwright & Co. | $195 → $248 | Maintains | Buy |
| 04/08/2021 | -11.98% | JP Morgan | $185 → $212 | Maintains | Overweight |
| 02/22/2021 | -18.62% | Credit Suisse | $169 → $196 | Maintains | Outperform |
| 02/16/2021 | 14.18% | Oppenheimer | $200 → $275 | Maintains | Outperform |
| 02/01/2021 | -19.04% | HC Wainwright & Co. | $125 → $195 | Upgrades | Neutral → Buy |
| 07/30/2020 | -31.49% | Oppenheimer | $155 → $165 | Maintains | Outperform |
| 07/30/2020 | 1.31% | Wedbush | $243 → $244 | Maintains | Outperform |
| 06/25/2020 | -39.8% | Credit Suisse | $129 → $145 | Maintains | Outperform |
| 06/25/2020 | -48.1% | HC Wainwright & Co. | $85 → $125 | Maintains | Neutral |
| 03/10/2020 | -48.93% | Jefferies | $115 → $123 | Upgrades | Hold → Buy |
| 02/27/2020 | -39.8% | Cowen & Co. | $119 → $145 | Upgrades | Market Perform → Outperform |
| 02/13/2020 | -49.76% | Credit Suisse | $113 → $121 | Maintains | Outperform |
| 01/31/2020 | -50.18% | JP Morgan | $116 → $120 | Upgrades | Neutral → Overweight |
| 08/01/2019 | -55.99% | Ladenburg Thalmann | $103 → $106 | Upgrades | Neutral → Buy |
| 08/01/2019 | -62.63% | Jefferies | → $90 | Upgrades | Underperform → Hold |
| 07/01/2019 | — | Credit Suisse | Upgrades | Neutral → Outperform | |
| 05/17/2019 | -60.97% | UBS | $115 → $94 | Upgrades | Sell → Neutral |
| 05/09/2019 | — | Credit Suisse | Upgrades | Underperform → Neutral | |
| 05/02/2019 | 13.35% | Wedbush | $269 → $273 | Maintains | Outperform |
| 03/01/2019 | -60.56% | Barclays | $100 → $95 | Maintains | Underweight |
| 11/19/2018 | -56.4% | Credit Suisse | $103 → $105 | Maintains | Underperform |
| 11/02/2018 | -47.69% | JP Morgan | $118 → $126 | Maintains | Neutral |
| 11/01/2018 | -57.23% | Credit Suisse | $106 → $103 | Maintains | Underperform |
| 10/12/2018 | — | Standpoint Research | Upgrades | Hold → Buy |
What is the target price for United Therapeutics (UTHR)?
The latest price target for United Therapeutics (NASDAQ: UTHR) was reported by HC Wainwright & Co. on August 3, 2023. The analyst firm set a price target for $300.00 expecting UTHR to rise to within 12 months (a possible 24.56% upside). 17 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for United Therapeutics (UTHR)?
The latest analyst rating for United Therapeutics (NASDAQ: UTHR) was provided by HC Wainwright & Co., and United Therapeutics reiterated their buy rating.
When is the next analyst rating going to be posted or updated for United Therapeutics (UTHR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of United Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for United Therapeutics was filed on August 3, 2023 so you should expect the next rating to be made available sometime around August 3, 2024.
Is the Analyst Rating United Therapeutics (UTHR) correct?
While ratings are subjective and will change, the latest United Therapeutics (UTHR) rating was a reiterated with a price target of $0.00 to $300.00. The current price United Therapeutics (UTHR) is trading at is $240.85, which is within the analyst's predicted range.